Antibody administration in experimental influenza increases survival and enhances the effect of oseltamivir英文文献资料.docVIP

Vol.4, Special Issue, 933-940 (2012) Health /10.4236/health.2012.430143 Antibody administration in experimental influenza increases survival and enhances the effect of oseltamivir 1,2* 2 1 Brit N. J. Pourroy , Hans J?rn Kolmos , Lars P. Nielsen 1 2 Department of Virology, Statens Serum Institute, Copenhagen, Denmark; Corresponding Author: brit@bsworld.dk * Research Unite of Clinical Microbiology, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark Received 16 September 2012; revised 14 October 2012; accepted 26 October 2012 ABSTRACT proposal of using convalescent plasma as an early con- trol measurement, in a future influenza pandemic or as treatment for severely ill patients, has been raised by several voices [2-6]. Anti-viral chemotherapy plays an important part in treating and preventing influenza illness. How- ever, its effectiveness in severe infections can be debated and a reoccurring problem is the emergence of resistant virus. Passive immuni- sation has for a long time been and is still used for prophylaxis and treatment of a number of in- fectious diseases. In this experimental study anti-influenza antibodies were passively admin- istrated to mice, subsequently they were in- fected with influenza virus and treated with ose- ltamivir. The aim was to investigate, if anti-in- fluenza antibodies influenced the out come of oseltamivir treatment and development of re- sistance towards oseltamivir. We show, that ose- ltamivir alone was not able to effectively prevent a fatal outcome, but that oseltamivir adminis- tered together with a limited amount of antibod- ies, resulted in improvement of the clinical con- dition of the mice. The results also showed that a higher dosage of antibodies alone were able to protect the mice from a lethal dose of virus.